Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.

ABSTRACT:

Background

There is an unmet need for antiretrovirals with novel mechanisms of action that can provide additional options for people with HIV-1. DOMINO evaluated the efficacy and safety of the maturation inhibitor GSK3640254 (GSK'254) plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults naive to antiretroviral therapy.

Methods

This partially blinded, multicentre phase 2b trial enrolled people with HIV-1 from 54 centres in ten countries (Argentina, Canada, France, Germany, Italy, Portugal, Russian Federation, South Africa, Spain, and the United States). Eligible participants were adults with plasma HIV-1 RNA ≥1000 copies/mL and CD4+ T-cell count ≥250 cells/mm³ who were naive to antiretroviral therapy. Participants were centrally randomised to rece

SUBMITTER: Joshi SR 

PROVIDER: S-EPMC12675029 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature